I am a postdoctoral researcher in Prof. Jonas Ludvigsson's group in the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, focusing mainly on the pharmaco-epidemiological research on inflammatory bowel disease, using data from ESPRESSO.
I had done my Ph.D research at Institute of Environmental Medicine, Karolinska Institutet. My doctoral thesis was exploring the role of biomedical factors in the risk and prognosis of amyotrophic lateral sclerosis.
Before that, I obtained my master's degree in Epidemiology and Biostatistics from the Fudan University, China in June 2016 and then worked as a biostatistician in Johnson & Johnson (China) Investments Ltd., Shanghai, China.
I excel at managing and analyzing real-world big data by using SAS. Other software including STATA, R, or Python works for me as well. I collaborated with other talented researchers and wrote a book (only have Chinese version) to introduce health workers to these four commonly used software from basic coding to advanced use. This book has been published by Tsinghua University Press in June 2021 (No. of pages: 623).
Link to this book: http://www.tup.tsinghua.edu.cn/booksCenter/book_08647801.html
The research questions of my current work include for example whether statin treatment reduces the risk of colorectal cancer among individuals with inflammatory bowel disease, or the health outcomes of individuals with a gastrointestinal biopsy result of normal mucosa (i.e., normal histological feature).
Except for gastrointestinal diseases, I have also conducted projects about the risk factors of neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis.
Various study designs (e.g., matched cohort study, matched case-control study, longitudianl study, and case-control study) in various datasets (e.g., Swedish national healthcare registers and nationwide gastrointestinal ESPRESSO histopathology cohort) are applied to answer the aforementioned questions.